Skip to Content

AstraZeneca PLC ADR AZN

Morningstar Rating
$76.90 −0.14 (0.18%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

AZN is trading at a 437% premium.
Price
$77.04
Fair Value
$41.00
Uncertainty
Medium
1-Star Price
$227.70
5-Star Price
$89.10
Economic Moat
Yfrtt
Capital Allocation
Bftdrgsvnb

Bulls Say, Bears Say

Bulls

The company is expanding its oncology presence with several important pipeline products. In particular, the company's EGFR drug Tagrisso looks well positioned to drive major cashflows over the next decade.

Bears

The company's strong entrenchment in respiratory disease could cause challenges, as pricing power in this market tends to be weak.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AZN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$77.04
Day Range
$76.6177.07
52-Week Range
$60.4777.94
Bid/Ask
$75.99 / $76.75
Market Cap
$238.43 Bil
Volume/Avg
2.8 Mil / 5.5 Mil

Key Statistics

Price/Earnings (Normalized)
20.85
Price/Sales
5.05
Dividend Yield (Trailing)
1.88%
Dividend Yield (Forward)
1.88%
Total Yield
1.88%

Company Profile

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Growth
Total Number of Employees
89,900

Competitors

Valuation

Metric
AZN
LLY
MRK
Price/Earnings (Normalized)
20.8582.4660.31
Price/Book Value
6.3857.208.21
Price/Sales
5.0519.395.43
Price/Cash Flow
23.8480.5819.09
Price/Earnings
AZN
LLY
MRK

Financial Strength

Metric
AZN
LLY
MRK
Quick Ratio
0.580.680.68
Current Ratio
0.821.351.25
Interest Coverage
5.1514.113.97
Quick Ratio
AZN
LLY
MRK

Profitability

Metric
AZN
LLY
MRK
Return on Assets (Normalized)
59.78%11.20%5.22%
Return on Equity (Normalized)
157.53%57.69%13.56%
Return on Invested Capital (Normalized)
88.21%20.65%8.29%
Return on Assets
AZN
LLY
MRK
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoRxvbkxsdyQbvd$732.9 Bil
JNJ
Johnson & JohnsonHnbnvqwqMnnfm$367.4 Bil
MRK
Merck & Co IncKvpslbtfsQrbq$331.5 Bil
ABBV
AbbVie IncRncpvvcbLgn$290.2 Bil
RHHBY
Roche Holding AG ADRCblnwnkssMkw$210.4 Bil
NVS
Novartis AG ADRYfjjkrclCsbx$209.8 Bil
AMGN
Amgen IncXxnqxxwnQbqkh$168.8 Bil
PFE
Pfizer IncHjwsgnfjKqwt$163.9 Bil
SNY
Sanofi SA ADRKvtwxzkVgfkg$122.4 Bil

Sponsor Center